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| INTRODUC TI ON
Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the fourth leading cause of cancer-related deaths in the world. 1 Patients with CRC are easily curable when diagnosed at an early stage, 2 thus the early diagnosis of CRC is crucial for the fight against this cancer. However, most CRC patients are diagnosed with middle or advanced stage disease. 3 Currently, established noninvasive tests, such as the guaiac-based fecal occult blood test, have a low sensitivity 4 and positive predictive value. 5, 6 Several serum protein biomarkers, including carcinoembryonic antigen, CA19.9, and CA125, can be used for monitoring the prognosis of CRC patients but none of them are recommended for the early diagnosis of CRC. 7, 8 The expression of TSP50 has also been proposed as a diagnostic signature for CRC, 9 but its sensitivity, specificity, and positive predictive value were 68.4%, 92.5%, and 95.6%, respectively. This signature is based on a risk score summarized from quantitative expression measurements of TSP50 protein, which lacks robustness for clinical applications due to large measurement batch effects. 10 In clinical practice, biopsy sampling with less invasive techniques, such as colonoscopy, are often used for the initial clinical evaluation of CRC. [11] [12] [13] [14] [15] However, an indeterminate diagnosis often creates a dilemma. 16 It has been reported that the miss rate of CRC after colonoscopy, which is the predominant screening and diagnostic test for CRC, 12, 17 is approximately 15% for patients with IBD. 12 Moreover, the biopsy location can be inaccurate, which might lead to inaccurately sampled adjacent nontumor tissues and degrading the diagnosis performance. 18 However, previously reported diagnostic signatures, such like the transcriptional signatures reported by Zheng et al 9 and our previous study, 10 all took tumor-adjacent normal tissues as the normal samples to obtain the signature. Thus, these signatures cannot classify inaccurately sampled CRC adjacent normal tissues to CRC. Given that the adjacent nontumor colorectal tissues of CRC patients might have some molecular characteristics of CRC, [19] [20] [21] it is possible to develop a signature to discriminate CRC (including CRC adjacent tissues) from tissues of nontumor (normal or IBD) individuals, which is suitable for minimum biopsy specimens and inaccurately sampled specimens.
Another major limitation of the previously reported transcriptional diagnostic signatures is that their applications are based on risk scores summarized from the quantitative expression measurements of the signature genes, [22] [23] [24] which are sensitive to batch effects and hardly applicable to individualized diagnoses. 10, [25] [26] [27] Notably, several reported quantitative transcriptional disease signatures, including AlloMap, 24 have been approved by the US FDA.
However, due to the existence of batch effects, the tissue samples must be sent to specific laboratories for measurement with strict quality control.
In contrast, the REOs of genes within individual samples, which are the qualitative transcriptional characteristics, are robust against experimental batch effects and can be directly applied to samples at the individualized level. [28] [29] [30] [31] The robustness property of the REO enables researchers to integrate multiple datasets produced by the same or similar platforms for developing disease signatures or classifiers, 32, 33 which makes it more likely to find robust signatures. 10, 32, 34 In addition, the qualitative transcriptional characteristics are highly robust against varied proportions of the tumor epithelial cell in specimens sampled from different tumor locations of the same patients, 26 partial RNA degradation during specimen preparation and storage, 25 and amplification bias for minimum specimens, 27 which are the common factors that lead to the failure of quantitative transcriptional signatures in clinical practice. Therefore, it is worth exploiting the within-sample REOs to identify a robust qualitative signature for the early diagnosis of CRC.
In this study, based on the robust within-sample REOs, we identified a qualitative transcriptional signature consisting of 7 gene pairs for the early diagnosis of CRC. The signature can accurately discriminate CRC tissues, including CRC adjacent normal tissues, from normal or IBD tissues of non-CRC individuals in both biopsy and surgical resection samples.
| MATERIAL S AND ME THODS

| Samples and data measurement
The gene expression profiles of 33 CRC biopsy specimens were measured by Affymetrix platform in our laboratory 35 and this study (NCT02770911) was approved by the Institutional Review Board at Fujian Medical University Union Hospital (No. 2015-23; Fuzhou, China). Written informed consents for all the 33 participants were obtained. The tumor biopsy specimens were obtained by endoscopy. RNA was extracted using the RNeasy Mini Kit (Qiagen), and was measured by Affymetrix GeneChip PrimeView Array. For the raw data (.CEL file) from the array platform, the Robust Multi-Array Average algorithm 36 was applied for background adjustment without quantile normalization.
We also measured 13 CRC surgical resection specimens, from 5 CRC patients, with the RNA-seq platform. This study was approved by the institutional review boards of all participating institutions, and written consent forms were obtained from all participants. For minimum biopsy specimens and inaccurately sampled specimens, and thus has potential value for clinical application.
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Of these, 2 specimens were excluded from the subsequent analysis due to poor RNA quality (RNA integrity number less than 6.0).
The proportion of tumor epithelial cells for each of the 13 tumor specimens, ranging from 40% to 100% (see Table 1 ), was measured by pathological section analysis. After surgical resection, the obtained cancer specimens were fresh-frozen for the subsequent RNA extraction. According to the manufacturer's protocol, total RNA was isolated from fresh-frozen CRC tissues using TRIzol reagent (Invitrogen) and the quality of RNA was assessed by Agilent 2200
TapeStation (Agilent Technologies). Then mRNA was captured from 1-2 μg total RNA using NEBNext PolyA mRNA Magnetic Isolation Module and stranded RNA-seq libraries were constructed using a NEBNext Ultra Directional RNA Library Prep Kit. Paired-end sequencing (2 × 150) was undertaken using an Illumina HiSeqXten and generated raw RNA-seq files (fastq) were preprocessed using Trimmomatic, 37 and the reference genome (GRCh37) was used to align reads using hisat2. 38 Finally, the fragments per kilobase of transcript per million fragments mapped values of genes were calculated using StringTie. 39 
| Public data and preprocessing
Multiple gene expression profiles were downloaded from the GEO repository (http://www.ncbi.nlm.nih.gov/geo/), ArrayExpress (http://www.ebi.ac.uk/array expre ss/), and TCGA (http://cance rgeno me.nih.gov/), as described in Table 2 For the array-based data, if multiple probes were mapped to a gene, the expression value of the gene was defined as the arithmetic mean of the values of the multiple probes. If a probe was mapped to zero or multiple genes, then the data of this probe were deleted.
For the sequence-based data from ArrayExpress, the gene symbols were mapped to Entrez gene ID with the biological database network. 40 For the sequence-based data from TCGA, the Ensembl gene IDs corresponding to the unique Entrez gene IDs of protein coding genes were used.
| Identification of REO-based CRC diagnosis signature
First, within a sample, the REO of two genes, i and j, is denoted where R i and R j represent the rank of gene i and gene j in a sample, respectively, and R ij is the rank difference between the 2 genes.
Obviously, the higher the reversal degree for a gene pair, the higher the cross-platform performance is for this gene pair. 
| Performance evaluation
Cancer samples, including cancer and cancer adjacent normal samples, were classified as positive samples; noncancer samples, including normal and IBD samples, were classified as negative samples. The performance of the signature was evaluated using sensitivity and specificity, which are calculated as follows:
where TP, TN, FP, and FN represent the number of true-positive, true-negative, false-positive, and false-negative samples, respectively.
The AUCs were calculated with the nonparametric Hanley-
McNeil algorithm 18 and 95% confidence intervals for AUCs were determined using an approximate normal distribution.
| RE SULTS
| Identification of the qualitative diagnostic signature
The analysis procedure of this study is described in Figure 1 .
First, using 30 normal samples and 65 IBD samples collected from 5 datasets measured by the Affymetrix platform (see Table 2 . We then used the top-ranked k pairs to classify samples according to the majority vote rule. The results showed that, for all possible k ranging from 1 to 7, the largest geometric mean of the sensitivity and specificity was 97.08% when k = 7 (Figure 2 ).
Thus, these 7 gene pairs, as described in Table 3 , were selected as the signature for discriminating CRC samples from noncancer 
| Validation of the diagnostic signature in independent datasets
We then validated the performance of the 7 gene pairs in multiple public datasets for biopsy and surgically resected samples. For a total of 977 cancer samples and 163 noncancer samples from these public databases, the geometric mean of the sensitivity and specificity was 96.80% and the AUC was 0.9589 (95% confidence interval, 0.9521-0.9657; Figure 3 ).
Notably, all the colorectal normal and IBD tissue samples from 
| Validation of the diagnostic signature in our data
To further validate the signature, using the RNA-seq platform, we additionally measured gene expression profiles of 13 CRC surgical Gene i has a higher expression level than gene j in CRC tissue samples compared with non-CRC tissue samples. resection specimens from 5 CRC patients, each with 3 specimens sampled from 3 tumor locations with different proportions of tumor epithelial cells (see Table 1 ). Two specimens were excluded from the gene expression measurements because of poor RNA quality.
All the 13 CRC specimens were correctly identified as CRC by our signature, even when the proportion of tumor epithelial cells was as low as 40%, which further verified that the REO-based signature is robust against varied proportions of tumor epithelial cells for the same patient with different tumor locations. 26 Moreover, for the 33 CRC biopsy specimens measured by the Affymetrix platform in our laboratory, 35 all of them were correctly identified as CRC based on our signature.
In summary, the above results together revealed that the signature can accurately discriminate CRC from non-CRC individuals using both surgical resection and biopsy samples measured by different platforms. In particular, the signature is robust against varied 42 ; we speculated that some of them might also have some characteristics of cancer.
Under many practical situations, with tissue biopsy sampling, it is difficult to obtain sufficient a quantity of RNA molecules for gene expression profiling or other molecular measurements. 18 Fortunately, our recent study showed that the REO-based signatures can be robustly applied to minimum specimens even with approximately 15 cancer cells. 27 Therefore, it is highly possible that the 7 gene pairs could be applicable for biopsy samples with minimum sampling amounts. Moreover, the REO-based signature was robust against varied proportions of tumor epithelial cells from the same patient with different tumor locations, 26 which is a common factor that could lead to the failure of the quantitative transcriptional signature in clinical practice. This study also showed that 13 specimens from 5 patients with different sampling locations, with different proportions of tumor epithelial cells (see Table 1 ), were correctly identified as CRC.
As for the other REO-based approaches, such as TSP and k-TSP, we additionally evaluated these approaches using the same training and validation datasets, as shown in One possible reason could be that the difference in the proportion of samples from the Affymetrix and RNA-seq platforms will bias the signature to the platform with larger samples when using the tspair R package and ktspair R package. In the training process for our REO signature, the gene pairs that were consistently detected in the data produced by the 2 platforms were used for the final signature selection (7 gene pairs in this study). Therefore, our method is intuitive and simple with the ability to identify very robust disease signatures.
Some genes in our signature, including AREG, SSBP1, KCNH2, and TRIM40, are well known CRC-related genes that might play a key role in the development of CRC. For example, AREG could induce the upregulation of EGFR, which is a key mediator of intestinal neoplastic transformation, and high gene expression level of AREG is a favorable prognostics biomarker for metastatic CRC. 43 Another gene, SSBP1, has highly abundant gene expression levels in CRC and is closely related with poor outcomes of CRC patients. 44 In cisplatin-resistant CRC cells, KCNH2 inhibitors had a synergistic action with cisplatin in triggering apoptosis and inhibiting proliferation. 45 Additionally, TRIM40 might provide therapeutic benefits, not only for inhibition of the growth of gastrointestinal cancers but also for the prevention of chronic IBDs. 46 In addition, ARHGAP10, 47 DHRS7, 48 and ZNF671 49 have also been reported to be closely correlated with other types of cancer, such as lung and prostate cancer. The above results indicated that the genes of the signature might play important roles in the carcinogenesis of CRC and these functions need to be further studied in future work.
In summary, our signature, consisting of 7 gene pairs, could robustly be applied for aiding the early diagnosis of CRC in multiple datasets of both biopsy and surgically resected samples, which is also suitable for minimum biopsy specimens and inaccurately sampled specimens. The clinical value of the 7 gene pairs for early diagnosis of CRC is worthy of further verification. Moreover, as the cost of high-throughput sequencing decreases markedly, for a limited amount of precious tissue sample at the clinical scene, we could measure all the genes or a set of genes of different biomarkers for diagnosis, histological classification, prognosis, and drug resistance evaluation of CRC ("a sequencing for all").
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